New research presented by Amplia Therapeutics (ASX:ATX) is drawing attention to a potential strategy that could improve the effectiveness of an emerging class of cancer treatments targeting KRAS mutations, one of the most widely studied drivers of solid tumours worldwide. …
New cancer research highlights potential of narmafotinib to koost KRAS Inhibitor therapies
March 9, 2026 Australian Biotech
Latest Video
New Stories
-
Alterity strengthens board with seasoned biotech leader as it advances flagship therapy
April 19, 2026 - -
Immuron posts steady global gains as Travelan drives third quarter sales growth
April 19, 2026 - - Australian Biotech -
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
New strategic alliance for Biointelect aims to fast track life sciences innovation
April 17, 2026 - - Latest News -
Why hospitals, and not medicines, dominate America’s health spending gap
April 17, 2026 - - Latest News -
Australia, the US, and their different choices about health system trade-offs
April 17, 2026 - - Latest News -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News